Green Cross' Biologics License Application for IVIG-SN submitted to FDA

November 24, 2015

Green Cross Corporation, a South Korean biopharmaceutical company, today announced that it has submitted its Biologics License Application for IVIG-SN (human normal immunoglobulin G for intravenous administration) to the United States Food and Drug Administration.

Previous Article
Green Cross' Biologics License Application for IVIG-SN submitted to FDA
Green Cross' Biologics License Application for IVIG-SN submitted to FDA

Green Cross Corporation, a South Korean biopharmaceutical company, today announced that it has submitted it...

Next Article
Early childhood Medicaid exposure linked to adult health outcomes
Early childhood Medicaid exposure linked to adult health outcomes

Expanding publicly funded health insurance to low-income children could have long-term benefits for adult h...